**TABLE E2.- PATIENT Characteristics- SLIT**

1. **Table E2a. Patient Characteristics- SLIT- Asthma**

| **Study** | **Patients randomized** | **Comparators** | **Age in years**  **Mean +/- SD (range)** | **Sex % male/female** | **Patients enrolled/ dropouts** | **Duration of Disease**  **(Mean years affected)** |
| --- | --- | --- | --- | --- | --- | --- |
| D'Ambrosio,  1999 1 | 30 | SLIT  Placebo | 32 +/- 17  32 +/- 18 | 50/50  43/57 | 14/0  16/0 | NR |
| Pajno,  2000 2 | 24 | SLIT  Placebo | 11(Range 8-15)  12 (Range 8-15) | 58/42  50/50 | 12/0  12/3 | 5 |
| Nelson,  1993 3 | 44 | SLIT  Placebo | Range: 20-74; males  18-46: females  Range: 25-48: males  19-40: females | 35/65  29/71 | 20/2  21/1 | NR |
| Cortellini  2010 4 | 27 | SLIT  Placebo | 19 +/- 7 (Range 16-42)  24 +/- 7 (Range 14-44) | 53/47  58/42 | 15/0  12/1 | 4.4 years  5.2 years |
| Stelmach, 2009 5  Penagos 20086 | 50 | SLIT  Placebo | 9 +/- 2  8 +/- 2 | 60/40  70/30 | 25/5  25/10 | NR |
| Lue,  2006 7 | 20 | SLIT  Placebo | 8 +/- 2  9 +/- 2 | 40/60  40/60 | 10/0  10/0 | 1 |
| Niu,  2006 8 | 110 | SLIT  Placebo | 8 +/- 2 (Range 5-11)  8+/- 2 (Range 5-12) | 61/39  58/42 | 56/7  54/6 | 1 |
| Sambugaro,  2003 9 | 58 | 8-day induction  15-day induction  20-day induction  Untreated | 19 (Range 4-43)  26 (Range 5-42)  17 (Range 6-41)  23 (Range 10-37) | 56/44  39/61  58/42  60/40 | 18/0  18/0  12/0  10/0 | NR |

1. **Table E2b. Patient Characteristics- SLIT- Asthma Rhinitis**

| **Study** | **Patients randomized** | **Comparators** | **Age in years**  **Mean +/- SD (range)** | **Sex % male/female** | **Patients enrolled/ dropouts** | **Duration of Disease**  **(Mean years affected)** |
| --- | --- | --- | --- | --- | --- | --- |
| Horiguchi,  2007 10 | 67 | SLIT  Placebo | 27 +/- 5  26 +/- 6 | 51/49  46/54 | 43/2  24/2 | 9 |
| Okubo,  200811 | 61 | SLIT  Placebo | 41/- 15  40+/- 15 | 49/51  32/68 | 37/0  22/0  2 dropouts before arm allocation | NR |
| Fujimura  2011 12 | 103 | SLIT  Placebo | 44.4 (Range 16-73)  42.3 (Range 19-70) | 34/66  22/78 | 51/15  37/10 | NR |
| Hordijk,  199813 | 69 | SLIT  Placebo | 28  28 | 52/48  43/57 | 27/8  30/6  Numbers as reported | NR |
| Tahamiler,  200714 | NR | SLIT /placebo  SLIT alone | 28+/- 10 (Range 12-51)  26+/- 8 (Range 10-49) | 54/46  54/46 | 67/NR  70/NR | 2  3 |
| Tseng,  200815 | 63 | SLIT  Placebo | 10 +/- 3  10 +/- 3 | 73/27  70/30 | 30/2  33/2 | 63%: 2-5, 33%: 6-10, 3%: 13  52%:2-5 ,48%: 6-10,0% :13 |
| deBot  201116 | 257 | SLIT  Placebo | 11.8 +/- 3.1  11.7 +/- 2.9 | 61/39  59/41 | 125/17  126/15  6 withdrew consent before arm allocation | 1. year |

**c)Table E2c. Patient Characteristics- SLIT- Asthma Rhinoconjunctivitis**

| **Study** | **Patients randomized** | **Comparators** | **Age in years**  **Mean +/- SD (range)** | **Sex % male/female** | **Patients enrolled/ dropouts** | **Duration of Disease**  **(Mean years affected)** |
| --- | --- | --- | --- | --- | --- | --- |
| D'Ambrosio,  199617 | 40 | SLIT  Pharmacotherapy | 30 (Range 18-41)  34 (Range 19-67) | 47/53  33/67 | 15/5  15/5 | 2 or more |
| la Rosa, 199918  Leonardi, 200919 | 41 | SLIT  Placebo | 10 (Range 6-14)  10 (Range 7-13) | 65/35  57/43 | 20/5  21/4 | 3  4 |
| Bowen,  200420 | 83 | SLIT  Placebo | 38 (Range 14-58)  35 (Range 16-56) | NR  NR | 43/15  40/11 | 19  17 |
| Skoner,  201021 | 115 | High dose SLIT  Medium dose SLIT  Placebo | 34 (Range 20-49)  34 (Range 19-49)  35 (Range 20-50) | 33/67  26/74  48/53 | 36/5  39/8  40/5 | NR |
| Di Rienzo,  200622 | 34 | SLIT  Placebo | 34+/- 10 (Range 18-55)  Entire Study | 47/53  Entire Study | 19/1  15/1 | NR |
| Makino,  201023 | 25 | SLIT  Placebo | 49+/- 15  48 +/- 13 | 67/34  69/31 | 9/0  15/1 | 2 |
| Horak, 1998  Austria 24 | 41 | SLIT  Placebo | 33+/- 15 (Range 18-38)  32 +/-16 (Range 18-38) | 36/64  (Entire study) | 20  21  (7 dropouts entire study) | 9 years |
| Lima  200225 | 56 | SLIT  Placebo | 34 (Range 21-53)  34 (Range 21-55) | 54/47  32/68 | 28/2  28/5 | 2 |
| Novembre,  200426 | 113 | SLIT  Control | 9 (Range 5-14)  8 (Range 4-16) | 70/30  70/30 | 54/6  59/10 | NR |
| Ott, 200827  Sieber 201228 | 213 | SLIT followed by placebo  Placebo | 33+/- 11  7.9- 64.7  34+/- 9  Range 7.9- 64.7 | 46/54  54/46 | 142/10  67/4 | 13 |
| Panzer,  200829 | 35 | SLIT  Placebo-SLIT | 17 +/- 9 (Range 7-50)  24 +/- 12 (Range 7-50) | 55/45  60/40 | 20/0  15/0 | NR |
| Roder,  200730 | 204 | SLIT  Placebo | 13+/- 7 (Range 7-17)  13+/- 3 (Range 6-17) | 67/33  44/56 | 108/26  96/24 | NR |
| Sabbah,  199431 | 58 | SLIT  Placebo | 23 +/- 10 (Range 13-43)  27 +/- 12 (Range 13-51) | 59/41  48/52 | 29/0  29/0 | 11  10 |
| Voltolini  2001 32 | 30 | SLIT  Placebo | 38 (Range 17-63)  39 (Range 24-64) | 47/53  27/73 | 15/1  15/2 | NR |

**d) Table E2d. Patient Characteristics- SLIT- Asthma Asthma and Rhinitis**

| **Study** | **Patients randomized** | **Comparators** | **Age in years**  **Mean +/- SD (range)** | **Sex % male/female** | **Patients enrolled/ dropouts** | **Duration of Disease**  **(Mean years affected)** |
| --- | --- | --- | --- | --- | --- | --- |
| Marogna,  200533 | 79 | SLIT  Placebo | 28 (Range 18-43)  29 (Range 19-45) | 55/45  57/44 | 39/10  40/17 | NR |
| Voltolini,  200934 | 24 | SLIT  Placebo | 44+/- 9  40 +/- 7 | 50/50  30/70 | 14/1  10/1 | NR |
| Marogna  201035 | 33 | SLIT  Montelukast | NR | NR | 17/1  16/3 | 2 years |
| Amar,  200936 | 58 | SLIT Monotherapy  SLIT Multiple allergen  Placebo | 39  36  39 | 26/74  41/59  47/53 | 19/0  17/3  17/2 | 2 years |
| Marogna,  200937 | 51 | SLIT  Budesonide | 27 +/- 1 (Range 17-41)  27 +/- 1 (Range 19-41) | 44/56  46/54 | 25/2  26/3 | 8  7 |
| Stelmach  201138 | 60 | SLIT pre-coseasonal  SLIT continuous  Placebo | 8.3  Range 5-17 | 65/35  74/26  61/39 | 20/3  20/1  20/2 | 2 years |
| Marogna,  200439 | 511 | SLIT  Control | 23 (Range 5-60)  22 (Range 5-58) | 56/44  63/37 | 319/48  192/22 | NR |
| Marogna,  200640 | 48 | SLIT - birch  SLIT - grass  SLIT - birch + grass  Control | 28  27  26  27 | NR  NR  NR  NR | 12/0  11/0  12/0  13/0 | NR |
| Marogna,  200841 | 216 | SLIT  Control | 11+/- 0  10 +/- 0 | 72/38  60/40 | 144/14  72/6 | 2 years |
| Moreno-Ancillo, 200742 | 105 | SLIT  Placebo | 29+/-10 (Range: 14-55)  26 +/- 8 (Range: 14-55) | 54/46  57/43 | 52/11  53/9 | 7 |
| Hirsch,  199743 | 30 | SLIT  Placebo | 11 (Range 6-15)  10 (Range 6-14) | 67/34  67/33 | 15/1  15/0 | 5 (asthma), 5 (rhinitis)  3 (asthma), 3 (rhinitis) |
| O'Hehir, 200944  O’Hehir, 200944 | 30 | SLIT  Placebo | 29+/- 8  38+/- 11 | NR  NR | 15/2  15/1 | Minimum 2 |
| Bush  201145 | 31 | SLIT high dose  SLIT Low dose  Placebo | 30.6 | 50/50  10/90  27/73 | 10/1  10/3  11/6 | 2 years |
| Tari,  199046 | 66 | SLIT  Placebo | Range 5-12  Range 5-12 | Entire study  64/36 | 34/4  32/4 | 3 years |
| Bahceciler,  200147 | 15 | SLIT  Placebo | Median 12 (Range 8-18)  Median 12 (Range 7-15) | 50/50  58/43 | 8/0  7/0 | Median 1.5  Median 3 |
| Guez,  200048 | 72 | SLIT  Placebo | 30+/- 12 (Range 12-51)  23 +/- 11 (Range 6-47) | 39/61  42/58 | 36/11  36/22 | 10  8 |
| Marogna  201049 | 78 | SLIT 3 yrs  SLIT 4 yrs  SLIT 5 yrs | 21.1 +/- 1.4  Range 15-34 | NR | 19/5  21/5  17/0  21/9 | 1. years |

**e)Table E2e. Patient Characteristics- SLIT- Asthma Asthma and Rhinoconjunctivitis**

| **Study** | **Patients randomized** | **Comparators** | **Age in years**  **Mean +/- SD (range)** | **Sex % male/female** | **Patients enrolled/ dropouts** | **Duration of Disease**  **(Mean years affected)** |
| --- | --- | --- | --- | --- | --- | --- |
| Pajno 200350,  Pajno 200451 | 30 | SLIT+ fluticasone  Placebo+fluticasone | 11 (Range 8-14)  11 (Range 8-14) | 47/53  40/60 | 15/1  15/2 | 5  3 |
| Passalacqua,  199952 | 30 | SLIT  Placebo | 33 (Range 22-47)  30 (Range 19-36) | 67/34  33/67 | 15/1  15/2 | 3  4 |
| Vervloet,  200753 | 76 | SLIT  Placebo | 39 (Range 22-60)  39 (Range 19-60) | 58/42  45/55 | 38/2  38/4 | 8  8 |
| Vourdas,  199854 | 69 | SLIT  Placebo | 12 (Range 8-17)  12 (Range 7-17) | 74/37  67/34 | 34/1  32/1  3 dropouts before arm allocation | 4  4 |
| Pajno  201155 | 80 | SLIT continuous;  SLIT co-seasonal | 11 (Range 8-16)  12 (Range 8-16) | 60/40  47/53 | 40/3  40/5 | 5.2 years  4.1 years |
| Feliziani,  199556 | 34 | SLIT  Placebo | NR | NR  NR | 18/0  16/0 | Minimum 2 |
| Pfaar,  200757 | 185 | SLIT  Placebo | 33 (Range 18-59)  34 (Range 17-55) | 66/34  59/41 | 94/45  91/36 | NR |
| Pradalier,  199958 | 126 | SLIT  Placebo | 28+/- 11 (Range 8-50)  30 +/- 12 (Range 7-58) | 47/53  59/41 | 62/3  61/4 | 9  5 |
| Valovirta,  200659  Savolainen, 200660 | 98 | SLIT High dose  SLIT Low dose  Placebo | 9 +/- 3  10 +/- 3  10 +/- 3 | 49/52  61/39  62/38 | 32/7  33/1  33/6 | 4  5  5 |
| de Blay,  200761 | 118 | SLIT  Placebo | 24+/- 7 (Range 12 -41)  27 +/- 8 (Range 12 -41) | 56/44  61/39 | 61/9  57/8 | 6  6 |
| Pozzan  201062 | 52 | SLIT  Placebo | 18 +/- 9  19+/-10 | 67/33  55/45 | 34/1  18/0 | 2 years |
| Alvarez-Cuesta, 200763 | 50 | SLIT  Placebo | 35 (Range 14-55)  Entire study | NR  NR | 25/8  25/9 | NR  NR |
| Ippoliti,  200364 | 86 | SLIT  Placebo | Median;9 (Range 5-12)  Median;9 , (Range 7-11) | 60/41  56/44 | 47/0  39/0 | 2  2 |
| Rodriguez,  200665 | 135 | SLIT  SLIT no 30d updosing | 23+/- 11 (Range 7-55)  22 +/- 10 (Range 7-55) | 55/45  47/53 | 69/6  66/6 | NR  NR |